Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis

This analysis (14 Phase III trials) found the combination of atezolizumab and bevacizumab was associated with superior results compared with other first-line agents. In the refractory setting, both regorafenib and cabozantinib ranked highest.

Source:

JAMA Oncology